Skip to main content
OpenTrials
Completed

NCT Number: NCT03759327

Angiomatoid Fibrous Histiocytoma: a Single Institution Case-series

single institution cases series review of histological and clinical data

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Angiomatoid Fibrous Histiocytoma Histiocytoma, Angiomatoid Fibrous

Sex eligibility

All sexes

Study type

Observational

Primary location

IRCC Rizzoli Orthopedic Institute

Bologna, 40136, Italy

About this study

single institution cases series review of histological and clinical data Investigators will retrieve from the archives of the Rizzoli Institute all the cases with a histological diagnosis of Angiomatoid Fibrous Histiocytoma. In all cases with enough available material, immunohistochemistry will be performed on slides/formalin-fixed paraffin-embedded tissue tumor material.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male and female patients treated at Rizzoli Institute from 01 January 2006 to 31 December 2017
  • Diagnosis of Angiomatoid Fibrous Histiocytoma
  • Histological slides/formalin-fixed paraffin-embedded tissue tumor (FFPE) blocks from archive available to perform the histology analysis
  • Written informed consent prior to any study-specific analysis and/or data collection

Exclusion criteria

  • Patients with histological diagnosis different from Angiomatoid Fibrous Histiocytoma

Treatment and study plan

Primary outcomes

  1. selection and review of 9 cases of Angiomatoid Fibrous Histiocytoma

    Time frame: at baseline (Day0)

    investigators will review all the medical records, radiological imaging, and histological slides of all cases to identify the best therapeutic approach.

  2. analysis of EWS-CREB1 and EWS-ATF1 mutation and ALK expression on tissue tumor material

    Time frame: at baseline (Day0)

    In all cases immunohistochemistry will be performed on slides/formalin-fixed paraffin-embedded tissue tumor material. EWS-CREB1 and EWS-ATF1 mutation and ALK expression will be analyzed with RT-PCR and/or FISH analysis.

Sponsors and collaborators

Lead sponsor

Istituto Ortopedico Rizzoli

Other

Registry information

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Nov 30, 2018
Registry last updated
Feb 13, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.